Story thread · 2 reports / 2 sources
RBC upgrades Lakefront Biotherapeutics stock rating on autoimmune drug potential
investing.com · 19h
First report: Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig — finance.yahoo.com, 2d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.